Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of sample-to-answer Detect-Ready® molecular diagnostic tests for the rapid detection of infectious diseases. The company has launched its first product, the Detect-Ready MRSA Panel, in several European countries with major MRSA screening initiatives, including Germany and the U.K., and in Australia. The Detect-Ready MRSA Panel allows for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA), a growing problem in hospitals and other health facilities around the globe. The screening panel is the first to include a wide range of critical clinical targets for S. aureus and related pathogens. In addition to MRSA, the panel detects methicillin-sensitive S. aureus (MSSA), methicillin-resistant non-S. aureus and mixed samples, which are frequently encountered in clinical practice.

MDI’s mission is to become a leading molecular diagnostics company leveraging its novel technologies to commercialize products for the accurate, rapid and cost-effective detection of infectious diseases. MDI’s Detect-Ready MRSA Panel is a real-time PCR test designed to provide increased accuracy, faster time to results and more efficient utilization of hospital resources than other MRSA diagnostic products. MDI is also developing Detect-Ready panels to test for the presence of other microbial agents, including C. difficile, sexually transmitted diseases (STDs) and foodborne pathogens. The company’s products are based on novel patent-pending technologies that provide greater accuracy and speed while simplifying kit storage and use.

MDI was founded in 2007 and is headquartered in Wayne, PA. It has research operations and an ISO 9001 and 13485 certified manufacturing facility in Israel.